Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance
- PMID:20123551
- DOI: 10.1016/S1353-8020(09)70826-0
Heterodimerization of dopamine receptors: new insights into functional and therapeutic significance
Abstract
G-protein-coupled receptors (GPCRs) exist both as monomers and also as dimers or higher-order oligomers, representing assemblies either with their peers or with other classes of GPCR ("heterodimers"). The pharmacological profiles of heterodimers often differ from the corresponding monomers or homodimers. Heterodimerization of dopamine receptors has been shown for both the D1/D5 and D2/D3/D4 receptor families, which couple positively and negatively, respectively, to adenylyl cyclase. Notably, heterodimers are formed by: D1 and adenosine A1 receptors; D2 or D3 and adenosine A2 receptors; and D2 and somatostatin SST5 receptors. Further, D1, D2 and D3 receptors physically assemble into functional D1/D2, D1/D3 and D2/D3 heterodimers possessing binding and coupling profiles distinct from the respective monomers. This article reviews data on dopamine D3/D2 and D3/D1 heterodimers, including observations that some antiparkinsonian agents--such as the preferential high-efficacy D3 versus D2 receptor agonists, pramipexole and ropinirole--show amplified potency at D3/D2 heterodimers versus constituent monomers, and others in contrast, such as the D3/D2 receptor agonist pergolide, show no difference. This article also discusses allosteric modulation amongst heterodimeric dopamine receptors, whereby agonist actions at one member of a heterodimer influence functional coupling at the other protomer. Finally, it presents data showing that, in cells co-transfected with D3 and D1 receptors, long-term exposure to pramipexole and ropinirole (which possess negligible affinities for D1 sites) elicits supersensitivity of D1 receptor-activated adenylyl cyclase, and conversely, D3/D2 receptor agonists such as apomorphine and bromocriptine (which also act as D1 receptor agonists) do not. A hypothetical relationship between these observations and the exacerbation of gambling in Parkinson's disease by antiparkinsonian agents is discussed.
Copyright 2009 Elsevier Ltd. All rights reserved.
Similar articles
- Differential induction of adenylyl cyclase supersensitivity by antiparkinson drugs acting as agonists at dopamine D1/D2/D3 receptors vs D2/D3 receptors only: parallel observations from co-transfected human and native cerebral receptors.Aloisi G, Silvano E, Rossi M, Millan MJ, Maggio R.Aloisi G, et al.Neuropharmacology. 2011 Feb-Mar;60(2-3):439-45. doi: 10.1016/j.neuropharm.2010.10.018. Epub 2010 Oct 28.Neuropharmacology. 2011.PMID:21035472
- Dopamine D2-D3 receptor heteromers: pharmacological properties and therapeutic significance.Maggio R, Millan MJ.Maggio R, et al.Curr Opin Pharmacol. 2010 Feb;10(1):100-7. doi: 10.1016/j.coph.2009.10.001. Epub 2009 Nov 5.Curr Opin Pharmacol. 2010.PMID:19896900Review.
- [The therapeutic plasma concentrations of antiparkinson dopamine agonists and their in vitro pharmacology at dopamine receptors].Tadori Y, Kobayashi H.Tadori Y, et al.Nihon Shinkei Seishin Yakurigaku Zasshi. 2014 Nov;34(5-6):127-32.Nihon Shinkei Seishin Yakurigaku Zasshi. 2014.PMID:25536763Review.Japanese.
- Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.Seeman P, Ko F, Willeit M, McCormick P, Ginovart N.Seeman P, et al.Synapse. 2005 Nov;58(2):122-8. doi: 10.1002/syn.20193.Synapse. 2005.PMID:16088951
- The peripheral dopaminergic system: morphological analysis, functional and clinical applications.Amenta F, Ricci A, Tayebati SK, Zaccheo D.Amenta F, et al.Ital J Anat Embryol. 2002 Jul-Sep;107(3):145-67.Ital J Anat Embryol. 2002.PMID:12437142Review.
Cited by
- Dopamine receptors in the anterior cingulate cortex implicate in nicotine enhanced morphine analgesia.Sardari M, Seddighfar M, Sardari S.Sardari M, et al.Psychopharmacology (Berl). 2021 Nov;238(11):3311-3323. doi: 10.1007/s00213-021-05947-z. Epub 2021 Aug 12.Psychopharmacology (Berl). 2021.PMID:34383109
- Optogenetic control of striatal dopamine release in rats.Bass CE, Grinevich VP, Vance ZB, Sullivan RP, Bonin KD, Budygin EA.Bass CE, et al.J Neurochem. 2010 Sep 1;114(5):1344-52. doi: 10.1111/j.1471-4159.2010.06850.x. Epub 2010 Jun 8.J Neurochem. 2010.PMID:20534006Free PMC article.
- Neuroprotection afforded by targeting G protein-coupled receptors in heteromers and by heteromer-selective drugs.Franco R, Navarro G.Franco R, et al.Front Pharmacol. 2023 Jul 13;14:1222158. doi: 10.3389/fphar.2023.1222158. eCollection 2023.Front Pharmacol. 2023.PMID:37521478Free PMC article.Review.
- The Dopamine D4 Receptor Regulates Gonadotropin-Releasing Hormone Neuron Excitability in Male Mice.Dairaghi L, Constantin S, Oh A, Shostak D, Wray S.Dairaghi L, et al.eNeuro. 2022 Mar 3;9(2):ENEURO.0461-21.2022. doi: 10.1523/ENEURO.0461-21.2022. Print 2022 Mar-Apr.eNeuro. 2022.PMID:35165199Free PMC article.
- Functional homomers and heteromers of dopamine D2L and D3 receptors co-exist at the cell surface.Pou C, Mannoury la Cour C, Stoddart LA, Millan MJ, Milligan G.Pou C, et al.J Biol Chem. 2012 Mar 16;287(12):8864-78. doi: 10.1074/jbc.M111.326678. Epub 2012 Jan 30.J Biol Chem. 2012.PMID:22291025Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical